Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib

Clinical and Translational Science

Volumn 2, Issue 3, 2009, Pages 183-192

  Hickinson, D Mark ^a   Marshall, Gayle B ^a   Beran, Garry J ^a   Varella Garcia, Marileila ^b   Mills, Elizabeth A ^a   South, Marie C ^a   Cassidy, Andrew M ^a   Acheson, Kerry L ^a   McWalter, Gael ^a   McCormack, Rose M ^a   Bunn, Paul A ^b   French, Tim ^a   Graham, Alex ^a   Holloway, Brian R ^a   Hirsch, Fred R ^b   Speake, Georgina ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Biomarker; Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI); FISH; Gefitinib; Personalized medicine

Indexed keywords

AMPHIREGULIN; ATP BINDING CASSETTE C5; BIOLOGICAL MARKER; CORTACTIN; CYTOKERATIN 16; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR 2; GEFITINIB; GLUTATHIONE TRANSFERASE P1; HYPOTHETICAL PROTEIN FLJ22662; MESSENGER RNA; ONCOPROTEIN; P21 ACTIVATED KINASE 6; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN;

ARTICLE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE COPY NUMBER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE NUMBER; GENOME ANALYSIS; GROWTH INHIBITION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SOMATIC MUTATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM PROTEINS; QUINAZOLINES; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 77953408158     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/j.1752-8062.2009.00099.x     Document Type: Article

References (33)

1. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol. 2001; 13: 506-513.
2. Boschelli DH. Small molecule inhibitors of receptor tyrosine kinases. Drugs Future. 1999; 24: 515-537.
3. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002; 62: 5749-5754.
4. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643-655.
5. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 1163-1167.
6. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5034-5042.
7. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 353: 133-144.
8. Cappuzzo F, Varella-Garcia M, Shigematsu H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Gregorc V, Toschi L, Franklin WA, Crino L, Gazdar AF, Bunn PA Jr, Hirsch FR. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol. 2005; 23: 5007-5018.
9. Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br J Cancer. 2005; 93: 1334-1340.
10. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR- and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol. 2006; 19: 634-640.
11. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, Kim MS, Sun DI, Lee YS, Jang JJ, Lee JY, Yoo NJ, Lee SH. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005; 11: 2879-2882.
12. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, Demard F. Characterization, quantifi cation, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck. 1991; 13: 132-139.
13. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998; 90: 824-832.
14. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA. 2003; 290: 2149-2158.
15. Thatcher N, Chang A, Parikh P, Rodrigues PJ, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005; 366: 1527-1537.
16. Amann J, Kalyankrishna S, Massion PP, Ohm JE, Girard L, Shigematsu H, Peyton M, Juroske D, Huang Y, Stuart SJ, Kim YH, Pollack JR, Yanagisawa K, Gazdar A, Minna JD, Kurie JM, Carbone DP. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005; 65: 226-235.
17. Cohen EEW, Rosen F, Stadler WM, Recant W, Stanson K, Huo D, Vokes EE. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003; 21: 1980-1987.
18. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol. 2002; 20: 3815-3825.
19. Stewart S, Cohen E, Licitra L, van Herpen CML, Khorprasert C, Soulieres D, Vodvarka P, Rischin D, Garin AM, Hirsch FR, Ghiorghiu S, Hargreaves L, Speake G, Armour A, Vokes E. A phase III randomized parallel-group study of gefitinib (IRESSA) versus methotrexate (IMEX) in patients with recurrent squamous cell carcinoma of the head and neck. Poster 3522. Proceedings of the American Association for Cancer Research; 2007; Los Angeles, CA, USA.
20. Charoenrat P, Rhys-Evans P, Eccles S. Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int J Cancer. 2000; 88: 759-765.
21. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001; 7: 2958-2970.
22. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res. 2003; 284: 31-53.
23. Guo M, Liu S, Herman JG, Zhuang H, Lu F. Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biol Ther. 2006; 5: 152-155.
24. Ingenuity® Systems. Available at: http://www.ingenuity.com. Accessed March 10, 2009.
25. Thomas EP, Dewhirst B, Todd J, Anim T, Downey-Jones M, Tilley D, Servenius B, Pawlowski K, Westcott A, Woodwark M, Firth M, Dix I. AstraZeneca Gene Catalogue - a novel view of the human transcriptome and proteome. ISMB ECCB; 2004; Glasgow, UK. (Presentation)
26. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD, Bunn PA, Jr. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res. 2006; 66: 944-950.
27. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007; 6: 1683-1691.
28. Charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA. C-erbB receptors in squamous cell carcinomas of the head and neck: Clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol. 2002; 38: 73-80.
29. Shintani S, Funayama T, Yoshihama Y, Alcalde RE, Matsumura T. Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. Cancer Lett. 1995; 95: 79-83.
30. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, Shih JY, Yang PC. Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response. Clin Cancer Res. 2008; 14: 4877-4882.
31. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005; 14: 133-144.
32. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006; 24: 5034-5042.
33. Parissenti AM, Hembruff SL, Villeneuve DJ, Veitch Z, Guo B, Eng J. Gene expression profiles as biomarkers for the prediction of chemotherapy drug response in human tumour cells. Anticancer Drugs. 2007; 18: 499-523.